VIRTUAL WEBINARS

We hope you will join our upcoming virtual webinar events! We are excited to be able to offer this venue as a great way to connect with other PAs within a virtual learning environment. If you are interested in attending, please register with the corresponding email links below. Hope to see you there!

Upcoming VIRTUAL Events:

TUESDAY, April 9, 2024 / 12 PM - 1 PM (EDT) / (Please See Below for Full Event Details)

Event Discussion:
Prurigo Nodularis: A Distinct, Chronic Skin Disease with Substantial Burden

To see the full series of events and register for a program, visit: https://itchingtolearnpn.com/event/chronic-spontaneous-urticaria-an-introduction-to-the-disease-features-pathophysiology-and-management-of-chronic-spontaneous-urticaria-csu-12/

Please See Below for Full Details of Events / Schedule Varies

Event Discussion:
Conversations in CSU Educational Programs | Chronic Spontaneous Urticaria
An introduction to the disease features, pathophysiology, and management of chronic spontaneous
urticaria (CSU).

To see the full series of events and register for a program, visit: CSUconversations.com

PREVIOUS VIRTUAL Events:

WEDNESDAY, May 17, 2023 / 6:30 PM (PT) / (Please See Below for Full Event Details)

Event Discussion: Addressing Barrier Dysfunction and Defects on Skin with Therapeutic Lotions, Creams and Ointments

Faculty Speaker: Andrea Nguyen, PA-C
First OC Dermatology / Irvine, CA

To Register for this exclusive event, please visit: http://www.skinacademy2020.com/3L3N3i

WEDNESDAY, March 29, 2023 / 6:30 PM (PT) / (Please See Below for Full Event Details)

Event Discussion: Optimal Formulations to Enhance Barrier Repair in Minor Wounds and Dry, Cracked Skin

Faculty Speaker: Andrea Nguyen, PA-C
First OC Dermatology / Irvine, CA

To Register for this exclusive event, please visit: http://www.skinacademy2020.com/5LKN0i

WEDNESDAY, November 2, 2022 / 6:00 PM (PT) / (Please See Below for Full Event Details)

Event Discussion: Advances in Therapeutic Moisturizers: Best Practices for the Treatment of Xerosis and Atopic Dermatitis.

Faculty Speaker: Joe Gorelick, NP

To Register for this exclusive event, please visit: http://www.skinacademy2020.com/5LHN0i

(**PLEASE NOTE** Participants are only allowed to attend ONE program topic per quarter.)

THURSDAY, August 11, 2022 / 6:00PM (PT & AZ) / 7:00 PM (MT)
EVENT DISCUSSION: The Essential Role for Photoprotection for Skin of All Color: Novel Sunscreen Formulas for UV and Free Radical Defense. (See full event details below)

SPEAKER: Joe Gorelick, NP / California Skin Institute

REGISTRATION: To register please visit: http://www.skinacademy2020.com/HLKN5i

WEDNESDAY, August 24, 2022 / 6:00PM (PT & AZ) / 7:00 PM (MT)
EVENT DISCUSSION: The Essential Role for Photoprotection for Skin of All Color: Novel Sunscreen Formulas for UV and Free Radical Defense. (See full event details below)

SPEAKER: Andrea Nguyen, PA-C, M.S. / First OC Dermatology

REGISTRATION: To register please visit: http://www.skinacademy2020.com/HLKN3i

MONDAY, JUNE 27, 2022 / 6:30 PM (PT) / (Please See Below for Full Event Details)

DermTech is hosting a Webinar Monday June 27th at 6:30pm please email: [email protected] Or [email protected] to receive the zoom link!
Learn more about the Power of Using Genemics to improve patient care.

(**PLEASE NOTE** Participants are only allowed to attend ONE program topic per quarter.)

WEDNESDAY, June 15, 2022 / 6:00PM (PT & AZ) / 7:00 PM (MT)
EVENT DISCUSSION: The Essential Role for Photoprotection for Skin of All Color: Novel Sunscreen Formulas for UV and Free Radical Defense. (See full event details below)

SPEAKER: Gina Fragione, MPAS, PA-C / First OC Dermatology

REGISTRATION: To register please visit: http://www.skinacademy2020.com/HLNN3i

WEDNESDAY, June 22, 2022 / 6:00PM (PT & AZ) / 7:00 PM (MT)
EVENT DISCUSSION: The Essential Role for Photoprotection for Skin of All Color: Novel Sunscreen Formulas for UV and Free Radical Defense. (See full event details below)

SPEAKER: Andrea Nguyen, PA-C / North Pacific Dermatology

REGISTRATION: To register please visit: http://www.skinacademy2020.com/HLNKKI

PRESENTATION: Modernizing Care of Patients with BCC: Changes in Management Approaches
(Earn 3 hours of CME Credit — See full details below.)

PRESENTED BY: Anne Lee, PA-C, MSPAS, MPH
Physician assistant
Dr. Brian Mekelburg Dermatology

WEBLINK: https://evolvemeded.gathered.com/invitation?ref=yMYerp2bOB

THURSDAY, MAY 26, 2022 / 12:15PM (PDT) / (Please See Below for Full Event Details)

EVENT: Melanoma Awareness Month brought to you by DermTech This THURSDAY May 26th at 12:15pm PDT.

SPEAKERS: Dr. Loren Clarke, Chief Medical Officer at DermTech and a DermPath, Dr. Brooke Brouha a West Dermatology clinician.

They will be sharing insights on the science and technology behind DermTech Melanoma Test and Dr. Brouha clinical experience with the test.

Please scan the QR code below to register!

Or Contact Mary Jean Tresse: [email protected]

TUESDAY, APRIL 5, 2022 /12:00 PM — 1:30PM (EST)
EVENT DISCUSSION: The RHA Collection featuring Virtual GurU Injections (See full event details below)

SPEAKER: Benji Dhillon, MD

REGISTRATION: To register please visit: www.revanceguru.com/registration Meeting ID: 2915

FOR QUESTIONS, PLEASE CONTACT: Emily Raso
Phone: 843-400-4600 x715
Email:  [email protected]

MONDAY, MARCH 21, 2022 /7:00PM - 8:30PM (EST)
EVENT DISCUSSION: The RHA Collection featuring Virtual GurU Injections (See full event details below)

SPEAKER: Jody Comstock, MD

REGISTRATION: To register please visit: www.revanceguru.com/registration Meeting ID: 2808

FOR QUESTIONS, PLEASE CONTACT: Emily Raso
Phone: 843-400-4600 x715
Email:  [email protected]

WEDNESDAY, MARCH 16, 2022 / 6:30 (PT)
EVENT DISCUSSION: This program will review the mechanism of action and information regarding
the safety and efficacy of WINLEVI in the treatment of acne vulgaris in patients
aged 12 years and older. (See full event details below)

FACULTY SPEAKER: Haleh Bakshandeh, MD / Dermatology Beverly Hills, CA


REGISTRATION: To register please visit: hlxregister.com Enter Invitation Code: RB2J5V


FOR QUESTIONS, PLEASE CONTACT: Jeffrey DeMoor
  phone: 714-614-8532
  email: [email protected]

TUESDAY, MARCH 1, 2022 / 8:00PM (ET), 7:00PM (CT), 6:00PM (MT), 5:00PM (PT)
EVENT DISCUSSION: Live from InnovateU: Introducing the DNA of RHA
(See full event details below)

SPEAKERS: Benji Dhillon, MBBS, MRCS, BSc Haley Wood, MSN, WHNP, CANS
Cosmetic Surgeon / Beaconsfield, UK   Nurse Practitioner / Franklin, TN

REGISTRATION: To register please visit: www.revanceguru.com/registration Meeting ID: 2864

FOR QUESTIONS, PLEASE CONTACT: Revance Injection Training Team
Phone: 843-400-4600
Email:  [email protected]

TUESDAY, FEBRUARY 15, 2022 / 5:30 (PT) / 8:30PM (ET)
EVENT DISCUSSION: Understanding how Anatomy Guides Results with The RHA Collection
(See full event details below)

FACULTY SPEAKERS: Authur Swift, MD, CM, FRSCS (c) AVA Shamban, MD
Plastic Surgeon / Swift Beauty     Board Certified Dermatologist / AVA MD

REGISTRATION: To register please visit: www.revanceguru.com/registration Meeting ID: 2664


FOR QUESTIONS, PLEASE CONTACT: Cara Chastain
Head of RHA Professional Marketing and Professional Education
  phone: 843-400-4600
  email:  [email protected]

THURSDAY, January 27, 2022 / 5:30PM (PST) / 6:30PM (MST)
EVENT DISCUSSION: Beyond Petrolatum: The Important Role Ingredients Have in the Treatment of Minor Wounds and Dry, Cracked Skin (See full event details below)

FACULTY SPEAKER: Rob Casquejo, PA-C / Skin and Cancer Center of Scottsdale

REGISTRATION: To register for this exclusive program, please visit:
  http://www.skinacademy2020.com/288

FOR QUESTIONS, PLEASE CONTACT: Kristi Toubbeh
  phone: 720-661-8338
  email: [email protected]

THURSDAY, February 3, 2022 / 5:30PM (PST) / 6:30PM (MST)
EVENT DISCUSSION: Beyond Petrolatum: The Important Role Ingredients Have in the Treatment of Minor Wounds and Dry, Cracked Skin (See full event details below)

FACULTY SPEAKER: Andrea Nguyen, PA-C, MPAS / First OC Dermatology

REGISTRATION: To register for this exclusive program, please visit:
http://www.skinacademy2020.com/287

FOR QUESTIONS, PLEASE CONTACT: Kristi Toubbeh
  phone: 720-661-8338
  email:  [email protected]

RELEASE DATE: December 15, 2021— EXPIRATION DATE: December 15, 2022
EVENT: Complimentary CME Webinar / Facilitating Beauty in Motion: Advanced HA Fillers for Dynamic Midface Rejuvenation (See full event details below)

FACULTY SPEAKER: Benjeev S. Dhillon, MBBS, BSc, MRCS
Medical Director / Define Clinic - London, Great Britian

REGISTRATION: To register for this exclusive program, please visit:
www.paradigmmc.com/1047e

TUESDAY, DECEMBER 14, 2021 / 5:30 (PT) / 8:30PM (ET)
EVENT DISCUSSION: Understanding how Anatomy Guides Results with The RHA Collection
(See full event details below)

FACULTY SPEAKERS: Authur Swift, MD, CM, FRSCS (c) AVA Shamban, MD
Plastic Surgeon / Swift Beauty     Board Certified Dermatologist / AVA MD

REGISTRATION: To register please visit: www.revanceguru.com/registration Meeting ID: 2590


FOR QUESTIONS, PLEASE CONTACT: Cara Chastain
Head of RHA Professional Marketing and Professional Education
  phone: 843-400-4600
  email:  [email protected]

THURSDAY, DECEMBER 02, 2021 / 5:30 (PT) / 6:30PM (MT)
EVENT DISCUSSION: Beyond Petrolatum: The Important Role Ingredients Have in the Treatment of Minor Wounds and Dry, Cracked Skin (See full event details below)

FACULTY SPEAKER: Gina Fragione / North Pacific Dermatology - Bellevue, WA

REGISTRATION: To register for this exclusive program, please visit:
  http://www.skinacademy2020.com/272

FOR QUESTIONS, PLEASE CONTACT: Niki Harmon
  phone: 203-354-6950
  email:  [email protected]

THURSDAY, DECEMBER 09, 2021 / 6:30 (PT) / 7:30PM (MT)
EVENT DISCUSSION: Beyond Petrolatum: The Important Role Ingredients Have in the Treatment of Minor Wounds and Dry, Cracked Skin (See full event details below)

FACULTY SPEAKER: Joe Gorelick / California Skin Institute - San Jose, CA

REGISTRATION: To register for this exclusive program, please visit:
http://www.skinacademy2020.com/273

FOR QUESTIONS, PLEASE CONTACT: Niki Harmon
  phone: 203-354-6950
  email:  [email protected]

THURSDAY, OCTOBER 28, 2021 / 6:00PM (PST)
PRESENTATION: Under My Skin - A Holistic Approach to Support the Health and Wellness of Patients With Psoriasis. (See full details below)

PRESENTED BY: Douglas DiRuggiero, PA / Skin Cancer and Cosmetic Dermatology Center / Rome, GA
(See full presentation details below)

REGISTRATION: Pre-Registration Weblink: https://us06web.zoom.us/meeting/register/tZYtf--gpjstHt0bLWS2JfuyeKIAoeOi33MZ
Event ID: 820 8688 0749 / Program Length: 1 hour

OCTOBER 22nd - 24th, 2021 / (FRIDAY 10/22/21 - SUNDAY 10/24/21)
VIRTUAL EVENT: Fourth Annual hybrid Integration Dermatology Symposium
REGISTRATION: To register for this event, please visit: integrativedermatologysymposium.com
(Enter Code: IDS25 for 25% off)
HOSTED BY: LearnSkin

PRESENTATION: Caring for Patients with Atopic Dermatitis: Incorporating
Pathophysiology into a Comprehensive Management Plan

PRESENTED BY: Anne Lee, PA-C, MSPAS, MPH
Physician assistant
Glendale Laser and Dermatology Associates

WEBLINK: Caring for Patients with Atopic Dermatitis: Incorporating Pathophysiology into a Comprehensive Management Plan

THURSDAY, AUGUST 12, 2021 / 5:45PM (PT) REGISTRATION
6:00PM (PT) PRESENTATION
EVENT DISCUSSION: Formation Considerations in Acne Vulgaris (Please see below for full details.)
PRESENTED BY: David Cotter, MD / Las Vegas Dermatology
REGISTRATION: To register for this event, please visit:  vyneprograms.com/rsvp  Enter Code: 1754

HOSTED BY: Joseph Lenz
phone: (916) 717-5897
email: [email protected]

TUESDAY, JUNE 8, 2021 AT 12:00 PM (PST)
WEBCAST: Understand the clinical profile, treatment durability, and dosing schedule of ILUMYA™ for the management of moderate‑to‑severe plaque psoriasis

SPEAKER: HOWARD SOFEN, MD / Dermatologist
LOS ANGELES, CA
(Speaker will be facilitating this program via webcast)

LOCATION: Dermatology Research Associates: Howard Sofen, MD
8930 S. Sepulveda Blvd., Suite 114
Los Angeles, CA 90045

To register, please go to hlxregister.com / Enter Program ID #: M8BMRF
RSVP or questions, please contact: Angela Bullard 323-394-7426 [email protected]

TUESDAY, JUNE 15, 2021 / 6:00PM (PT)
EVENT DISCUSSION: WHY IT'S IMPORTANT TO TREAT NEUROVASCULAR DYSREGULATION
   IN ROSACEA (See full details below)

PRESENTED BY: Dr. Hilary Baldwin

REGISTRATION: To register, please email: [email protected]

THURSDAY, MAY 20, 2021 AT - 5:15 PM (PST) REGISTRATION
5:30 PM (PST) PRESENTATION
WEBCAST: Zilxi (Minocycline) topical foam,1.5% - The first and only topical minocycline approved
 for the treatment of inflammatory lesions of rosacea

PRESENTED BY: Hilary Baldwin, MD
Rutgers Robert Wood Johnson Medical Center / Virtual Webcast, CA

HOSTED BY: Joseph Lenz
  916-717-5897

To register for this event, please visit vyneprograms.com/rsvp / Event Code: 1565

THURSDAY, MARCH 18, 2021 / 6:30PM (PST)
INTERACTIVE: Advances in Therapeutic Moisturizers: Best Practices for Treatment of Xerosis (See full details below)

PRESENTED BY: Joe Gorelick, NP / California Skin Institute
(See full presentation details below)

REGISTRATION: Please confirm your availability for this session by visiting: http://www.skinacademy2020.com/179

If you have questions, or would like more information please contact
Niki Harmon (203) 354-6950 or email [email protected]

WEDNESDAY, MARCH 24, 2021 / 6:00PM (PST)
PRESENTATION: Chronic Inflammatory Diseases: The Influence of the Microbiome and Considerations
for Holistic Patient Care (Microbiome) (See full details below)

PRESENTED BY: Douglas DiRuggiero, PA / Skin Cancer and Cosmetic Dermatology Center / Rome, GA
(See full presentation details below)

REGISTRATION: Pre-Registration Weblink: https://zoom.us/meeting/register/tJEpcugrj0uGNFXyZ_pWQZokKMSWsbkNm99
Event ID: 954 4280 6425 / Program Length: 1 hour

WEDNESDAY, MARCH 17, 2021 / 5:30PM (PT) - Registration / 6:00PM (PT) - Presentation
PRESENTATION:   ZILXI™ (minocycline) topical foam, 1.5%
The first and only topical minocycline approved for
the treatment of inflammatory lesions of rosacea. (See full presentation details below)

PRESENTED BY: Neal Bhatia, MD / Therapeutics Clinical Research
   (See full presentation details below)

REGISTRATION: To register for this event, please visit: wyneprograms.com/rsvp Event Code: 1507

HOSTED BY: Joseph Lentz  (916) 717-5897

THURSDAY, MARCH 18, 2021 / 12:45PM - 1:30PM (PST) / 3:45PM - 4:30PM (EST)
FRIDAY, MARCH 19, 2021 / 9:45AM - 10:30AM (PST) / 12:45PM - 1:30PM (EST)

PRESENTATION:   Coffee Talk with Dr. Zeichner and EPI Health
(See full presentation details below)

PRESENTED BY: Joshua Zeichner, MD, FAAC
 Brett Fair, Head of Commercial Operations at EPI Health

EVENT LINK: To attend these events, please visit: http://bit.ly/epicoffeetalk

TUESDAY, MARCH 23, 2021 / 4:00-5:30PM (PDT)
PRESENTATION: Red Faces and Understanding the Evaluation and Management
of Persistent Facial Erythema in Adults with Rosacea

PRESENTED BY: Leon Kircik, MD, FAAD
Joshua Zeichner, MD
Director of Cosmetic Research in Dermatology at Mount Sinai Hospital, NYC

REGISTRATION: Registration Weblink: https://register.gotowebinar.com/register/6508074609207952400

TUESDAY, MARCH 2, 2021 AT 12:15 PM (PST)
VIRTUAL MEETING: Patient Scenarios for the Use of Topical Corticosteroids in Psoriasis &
Corticosteroid-Responsive Dermatoses

PRESENTED BY: Daniel Carrasco, MD
Sanova Dermatology
Austin, TX

REGISTRATION: To register, please go to: hlxregister.com / Enter Program ID # 67GDGD
To RSVP, or if you have questions,
please contact: Jeffrey DeMoor
714-614-8532
[email protected]

Patient scenarios for the use of topical corticosteroids in psorias & Corticosteroid-Responsive dermatoses

INDICATIONS AND USAGEHALOG® Solution (Halcinonide Topical Solution, USP) 0.1%, HALOG (Halcinonide Cream, USP) 0.1% and HALOG (Halcinonide OINTMENT, USP) 0.1% are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

IMPORTANT SAFETY INFORMATIONCONTRAINDICATIONS
Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations.

PRECAUTIONS
Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria in some patients.
Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings. Application to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests, and for impairment of thermal homeostasis. If HPA axis suppression or elevation of the body temperature occurs, an attempt should be made to withdraw the drug, to reduce the frequency of application, substitute a less potent steroid, or use a sequential approach when utilizing the occlusive technique.
Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity. Administration of topical corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children.
In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.
Use in Specific Populations
Topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.
Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Caution should be exercised when topical corticosteroids are administered to a nursing woman.
Adverse Reactions
The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings (reactions are listed in an approximate decreasing order of occurrence): burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria.
Please see Full Prescribing Information.
If you experience any Adverse Events you are encouraged to report them to the Drug Safety Department at 1-800-406-7984 or email [email protected]. You can also report to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

MONDAY, FEBRUARY 22, 2021 / 5:15PM (PST) - REGISTRATION
5:30PM (PST) - PRESENTATION

VIRTUAL PROGRAM: Amzeeq® (minocycline) Topical Foam, 4% The First and Only Topical
Minocycline for Moderate to Severe Acne Vulgaris (See below for full details)

PRESENTED BY: Hilary Baldwin, MD
Rutgers Robert Wood Johnson Medical Center

REGISTRATION: To register, please visit: vyneprograms.com/rsvp / Enter Program Code: 1454

HOSTED BY: Joseph Lenz / 916-717-5897

WEDNESDAY, FEBRUARY 17, 2021 /7:00PM - 9:00PM (EST)

INTERACTIVE: THE PROACTIVE APPROACH TO TREATING ACNE & ROSAECA (See full details below)

PRESENTED BY: Heather Woolery-Loyd, MD / Hilary Baldwin, MD / Julie Harper, MD
(See full presentation details below)

REGISTRATION: To register, please visit: http://bit.ly/BC21721

TUESDAY, JANUARY 26, 2021 AT 12:00 PM TO 1:00 PM (PST)
WEBINAR: TREMFYA® SHORT COURSE: A FIRST-LINE BIOLOGIC IN ADULT PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS AND ALSO APPROVED FOR ADULT
PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS

PRESENTED BY: Jennifer Soung MD
Director of Clinical Research, Clinical Instructor
@ Harbor Univ. of CA Los Angeles / Santa Ana
1510 S. Central Ave #470
Glendale, CA 91204

REGISTRATION: To register, log on to www.mydomeprogramregistration.com
and enter meeting code: 2020-02186
If you have questions about this program, please call {(877) 468-6720}.
We look forward to your participation in this informative discussion.

TREMFYA® SHORT COURSE:
A FIRST-LINE BIOLOGIC IN ADULT PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS AND ALSO APPROVED FOR ADULT PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS

INDICATIONS
TREMFYA® is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

TREMFYA® is indicated for the treatment of adults with active psoriatic arthritis.

DOSAGE AND ADMINISTRATION
TREMFYA® is administered as a 100 mg subcutaneous injection once every 8 weeks, after starter doses at weeks 0 and 4. In active psoriatic arthritis, TREMFYA® may be administered alone or in combination with a cDMARD (e.g., methotrexate).

TREMFYA® is intended for use under the guidance and supervision of a physician. Patients may self-inject with TREMFYA® after physician approval and proper training.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS
TREMFYA® is contraindicated in patients with a history of serious hypersensitivity reaction to guselkumab or to any of the excipients.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions
Serious hypersensitivity reactions, including anaphylaxis, have been reported with postmarket use of TREMFYA®. Some cases required hospitalization. If a serious hypersensitivity reaction occurs, discontinue TREMFYA® and initiate appropriate therapy.

Infections
TREMFYA® may increase the risk of infection. Treatment with TREMFYA® should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated.

Consider the risks and benefits of treatment prior to prescribing TREMFYA® in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving TREMFYA® to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and discontinue TREMFYA® until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis (TB)
Evaluate patients for TB infection prior to initiating treatment with TREMFYA®. Initiate treatment of latent TB prior to administering TREMFYA®. Monitor patients for signs and symptoms of active TB during and after TREMFYA® treatment. Do not administer TREMFYA® to patients with active TB infection.

Immunizations
Prior to initiating TREMFYA®, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with TREMFYA®.

ADVERSE REACTIONS
Most common (≥1%) adverse reactions associated with TREMFYA® include upper respiratory infections, headache, injection site reactions, arthralgia, bronchitis, diarrhea, gastroenteritis, tinea infections, and herpes simplex infections.

The overall safety profile observed in patients with psoriatic arthritis is generally consistent with the safety profile in patients with plaque psoriasis, with the addition of bronchitis and neutrophil count decreased.

Please read the full Prescribing Information and Medication Guide for TREMFYA®. Provide the Medication Guide to your patients and encourage discussion.

cp-82625v3

DISCLOSURE

In adherence with PhRMA guidelines, spouses or other guests are not permitted to attend company-sponsored programs.

For all attendees, please be advised that information such as your name and the value and purpose of any educational item, meal, or other items of value you receive may be publicly disclosed. If you are licensed in any state or other jurisdiction, or are an employee or contractor of any organization or governmental entity that limits or prohibits meals from pharmaceutical companies, please identify yourself so that you (and we) are able to comply with such requirements.

Please note that the company prohibits the offering of gifts, gratuities, or meals to federal government employees/officials. Thank you for your cooperation.

This promotional educational activity is not accredited. The program content is developed by Janssen Biotech, Inc. Speakers present on behalf of the company and are required to present information in compliance with FDA requirements for communications about its medicines.

If at any time you have any questions, including
questions about the use of your email in this regard
and our Privacy Policy, please do not hesitate to
contact me. Thank you for your consideration.

© Janssen Biotech, Inc. 2020 11/20 cp‑185822v1
Janssen Biotech, Inc. | 800 Ridgeview Drive | Horsham, PA 19044

TUESDAY, JANUARY 19, 2021 AT 5:30 PM (PST)
VIRTUAL MEETING: Regeneron Healthcare Solutions / Sanofi Sponsorship
**Special Educational Program Opportunity for PA Members**
HOSTED BY: Vishi Hawkes & Marie Olsen
CONTACT: For more information please email Vishi Hawkes at [email protected]

FREE 6 Month Access to Visual Dx via the Regeneron-provided special access code activation. (One-time activation applies.)
Special Educational Program for Dermatology Diagnosis, Treatment, and Photo App
$99.00 Program Value / Per The Physician Payments Sunshine Act (PPSA)
Interested Members can attend virtual meeting for details or email Vishi Hawkes at [email protected] for program details and access.

THURSDAY, DECEMBER 10, 2020 AT 12:30 PM (PST)
WEBINAR: DermTech PLA & PLAplus Precision Genomics for the Early Detection of Melanoma

SPEAKER: Brook Brouha, MD, PhD
Board Certified Dermatologist & Dermatopathologist

REGISTRATION: Please registrar in advance at: https://CVENT.ME/4BkGRI

THURSDAY, DECEMBER 10, 2020

5:00 PM (PT) - REGISTRATION
5:30 PM (PT) - PRESENTATION

WEBINAR: VIRTUAL DINNER PRESENTATION on Zilxi ™ (minocycline) topical foam, 1.5%
The first and only topical minocycline approved for the treatment of inflammatory
lesions of rosacea.

PRESENTED BY: Hilary Baldwin, MD
Rutgers Robert Wood Johnson Medical Center

HOSTED BY: JOSEPH LENZ / (916) 717-5897

REGISTRATION: To register for this event, please visit: vyneprograms.com/rsvp
and enter the Event Code: 1393
(Login details will be provided upon registration)

This is a promotional program and no CME credits are offered.
Pursuant to the PhRMA Code on Interactions with Health Care Professionals, attendance at this promotional program is restricted to healthcare professionals. Accordingly, spouses and other guests who are not healthcare professionals may not attend this event.

VYNE will report transfers of value made to US healthcare professionals to the extent required by federal and state laws, as applicable

IMPORTANT SAFETY INFORMATION

Please click here for full Prescribing Information.

Your privacy is important to us. For more information on how VYNE protects your privacy and how we use your personal data, please view our Privacy Policy and Terms of Use. If you would prefer not to receive emails from us, please do not reply to this message, and instead email us at [email protected]. Please allow up to seven days for your email address to be removed.

WEDNESDAY, DECEMBER 9, 2020 AT 6:00 PM (MST)
WEBINAR: More than Skin Deep: A Joint Approach to Managing Psoriatic Disease (PSO/PsA)
-- Version October 2020

PRESENTED BY: Jennifer Soung, MD Southern California Dermatology
MEETING WEBLINK: https://zoom.us/j/99873001822
Program Length: 45 Minutes
Event ID: 998 7300 1822

PLEASE RSVP to Ken Webert at [email protected], 208-996-4508.

MONDAY, NOVEMBER 23, 2020 AT 12:15 PM (PST)
WEBINAR: Understand the clinical profile, treatment durability, and dosing schedule of ILUMYA™ for the management of moderate‑to‑severe plaque psoriasis
SPEAKERS: Paul Yamauchi, MD / Dermatologist
Dermatology Institute and Skin Care Center in Santa Monica, Santa Monica, CA
To register, please go to hlxregister.com / Enter Program ID #: TTQ8N4
RSVP or questions, please contact: Angela Bullard [email protected]

INDICATION
ILUMYA™ (tildrakizumab‑asmn) is indicated for the treatment of adults with moderate‑to‑severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Please see Important Safety Information (on reverse, next page). In accordance with current PhRMA guidelines, guests (spouse, family, etc.) are not permitted. We appreciate your understanding and support of our commitment to follow the highest ethical standards in all our interactions with healthcare professionals.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS
ILUMYA™ is contraindicated in patients with a previous serious hypersensitivity reaction to tildrakizumab or to any of the excipients.

WARNINGS AND PRECAUTIONS
Hypersensitivity
Cases of angioedema and urticaria occurred in ILUMYA™-treated subjects in clinical trials. If a serious allergic reaction occurs, discontinue ILUMYA™ immediately and initiate appropriate therapy.

Infections
ILUMYA™ may increase the risk of infection. Treatment with ILUMYA™ should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated.

Consider the risks and benefits of treatment prior to prescribing ILUMYA™ in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving ILUMYA™ to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and consider discontinuation of ILUMYA™ until the infection resolves.

Pretreatment Evaluation for Tuberculosis
Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with ILUMYA™. Do not administer ILUMYA™ to patients with active TB infection. Initiate treatment of latent TB prior to administering ILUMYA™. Consider anti-TB therapy prior to initiation of ILUMYA™ in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Patients receiving ILUMYA™ should be monitored closely for signs and symptoms of active TB during and after treatment.

Immunizations
Prior to initiating therapy with ILUMYA™, consider completion of all age-appropriate immunizations according to current immunization guidelines. Patients treated with ILUMYA™ should not receive live vaccines.

Adverse Reactions
The most common (≥1%) adverse reactions associated with ILUMYA™ treatment that were more frequent than in the placebo group are upper respiratory infections, injection-site reactions, and diarrhea.

For additional safety information, please see the full Prescribing Information and Medication Guide at https://www.ilumyapro.com.

SUN Dermatology is a division of Sun Pharmaceutical Industries, Inc.
© 2020 Sun Pharmaceutical Industries, Inc. All rights reserved.
ILUMYA is a trademark of Sun Pharma Global FZE. PM-US-ILY-0805

TUESDAY, NOVEMBER 17, 2020 AT 12:15 PM (PST)
WEBINAR: LEO Pharma invites you to an EDUCATIONAL SPEAKER PROGRAM to learn more about Finacea Foam®
SPEAKERS: Joe Gorelick, MSN, FNP-C
LOCATION: Microsoft Teams
To registrar for this program please contact:
Michaelangelo Cruz at [email protected] or call 1-310-902-6148
(NOTE: If you call goes to voicemail when you RSVP, please leave your name and number and you will receive a call back to confirm your attendance.)
- Speaker is a paid consultant of LEO Pharma.

State/Federal Laws and Restrictions: LEO Pharma, Inc. abides by the PhRMA Code on interactions with Healthcare Professionals and is committed to complying with state laws related to our interactions with healthcare practitioners.

Please visit www.finaceafoam.com for product-related information.

THURSDAY, NOVEMBER 12, 2020 / 5 SESSIONS AVAILABLE
WEBINAR: Introducing Seysara® (sarecycline)
SPEAKERS: Hilary Baldwin, MD & Emmy Graber, MD
- RSVP for the session below that best fits your schedule and submit questions ahead of time:

See how SEYSARA can help treat moderate to severe acne. There’s new information and an updated FDA label for SEYSARA and we want you to be the first to learn about it. Almirall invites you to join an interactive, virtual session alongside disease area experts to discuss this new and exciting update!

INDICATIONS AND USAGE
SEYSARA (sarecycline) tablet, is indicated for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older.

Limitations of Use: Efficacy of SEYSARA beyond 12 weeks and safety beyond 12 months have not been established. SEYSARA has not been evaluated in the treatment of infections. To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, SEYSARA should be used only as indicated.

IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
SEYSARA is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines.

WARNINGS AND PRECAUTIONS

• Like other tetracyclines, SEYSARA can cause fetal harm when administered to a pregnant woman. If SEYSARA is used during pregnancy, or if the patient becomes pregnant while taking SEYSARA, the patient should be informed of the potential hazard to the fetus and treatment should be stopped immediately.

• The use of SEYSARA during tooth development (second and third trimesters of pregnancy, infancy, and childhood up to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown)..

• Clostridium difficile associated diarrhea (CDAD) has been reported with nearly all antibacterial agents, and may range in severity from mild diarrhea to fatal colitis. If Clostridium difficile Associated Diarrhea (antibiotic associated colitis) occurs, discontinue SEYSARA.

• Central nervous system side effects, including light-headedness, dizziness or vertigo, have been reported with tetracycline use. Patients who experience these symptoms should be cautioned about driving vehicles or using hazardous machinery. These symptoms may appear during therapy and may disappear when the drug is discontinued.

• Intracranial hypertension in adults and adolescents has been associated with the use of tetracyclines. Clinical manifestations include headache, blurred vision and papilledema. Although signs and symptoms of intracranial hypertension resolve after discontinuation of treatment, the possibility for sequelae such as visual loss that may be permanent or severe exists. Concomitant use of isotretinoin and SEYSARA should be avoided because isotretinoin, a systemic retinoid, is also known to cause intracranial hypertension.

• Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. Patients should minimize or avoid exposure to natural or artificial sunlight (tanning beds or UVA/B treatment) while using SEYSARA.

• Bacterial resistance to tetracyclines may develop in patients using SEYSARA. Because of the potential for drug-resistant bacteria to develop during the use of SEYSARA, it should only be used as indicated.

• As with other antibiotic preparations, use of SEYSARA may result in overgrowth of non-susceptible organisms, including fungi. If superinfection occurs, SEYSARA should be discontinued and appropriate therapy instituted.

Please see accompanying Full Prescribing Information.

Tuesday, October 20, 2020 at 6:30 pm (PST)
Webinar: The Essential Role of Therapeutic Moisturizers in the Treatment of Xerosis
Speaker: Joe Gorelick, NP
*Register and receive a Beiersdorf Care Package with several Eucerin products that will be utilized during the program, and a $50 GrubHub code to be used on or after the event.
Please sign up by visiting: http://www.skinacademy2020.com/97
With any other questions, please contact Michael Midgette at (203) 604-1864 or email [email protected]

Thursday, October 8, 2020 at 6:30 pm (PST)
Webinar: The Essential Role of Therapeutic Moisturizers in the Treatment of Atopic Dermatitis
Speaker: Joe Gorelick, NP
*Register and receive a Beiersdorf Care Package with several Eucerin products that will be utilized during the program, and a $50 GrubHub code to be used on or after the event.
Please sign up by visiting: http://www.skinacademy2020.com/94
With any other questions, please contact Michael Midgette at (203) 604-1864 or email [email protected]

Wednesday, September 30, 2020 at 6 pm (PST)
Webinar: Absorica LD
Register with [email protected]

Tuesday, September 29, 2020 at 12 pm (PST)
Webinar: AbbVie MSL Update
RE: Severe COVID-19 risk in patients on biologics or who have immune medicated inflammatory diseases.
Register with: [email protected]

JOIN US FOR LEARNING AND FUN